MetaCap

Fennec Pharmaceuticals (FENC) vs IRulya Therapeutics (IRLA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fennec Pharmaceuticals is the larger company by market cap ($462.1 million vs $432.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FENC+11.69%IRLA+17.16%
+21%-1%-24%
Aug 14, 20261 yearNov 20, 2026
FENC+11.69%IRLA+17.16%
+19%+0%-18%
Aug 10, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FENC versus IRLA key metrics
MetricFENCIRLA
Share price$13.09$39.88
Market cap$462.14M$432.36M
1-day change-2.68%-0.15%
YTD return+70.00%—
1-year return+66.12%—
5-year return+35.79%—
P/E ratio (TTM)436.33—
Forward P/E12.47—
EPS (TTM)$0.03$-162.79
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$44.64M—
Revenue growth (YoY)-6.09%—
Net income (latest FY)$-9.74M$-83.98M
Operating margin-14.07%—
Net margin-21.82%—
52-week high$13.85$910.00
52-week low$5.65$15.10
Distance from 52-week high-5.49%-95.62%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+34.45%+90.90%
Average volume220.87K63.03K
Shares outstanding35.31M10.84M
Employees3538
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Fennec Pharmaceuticals

FENC stock →

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees

About IRulya Therapeutics

IRLA stock →

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees

FENC vs IRLA FAQ

Which is bigger, Fennec Pharmaceuticals or IRulya Therapeutics?

Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $462.14M compared with $432.36M for IRulya Therapeutics (IRLA).

Are Fennec Pharmaceuticals and IRulya Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons